Endpoints in diabetes cardiovascular outcome trials

Lancet. 2018 Jun 16;391(10138):2412. doi: 10.1016/S0140-6736(18)31184-X.

Authors

Tejas Patel¹, Bereket Tesfaldet², Iffat Chowdhury², Anna Kettermann², James P Smith², Frank Pucino², Eileen E Navarro Almario²

Affiliations

¹ US Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: [email protected].
² US Food and Drug Administration, Silver Spring, MD 20993, USA.

PMID: 29916379
DOI: 10.1016/S0140-6736(18)31184-X

No abstract available

Publication types

Comparative Study
Letter
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Cardiovascular Diseases / mortality*
Clinical Trials as Topic*
Endpoint Determination*
Heart Failure / epidemiology
Hospitalization / statistics & numerical data
Humans
Hypoglycemic Agents / adverse effects*
Myocardial Infarction / epidemiology
Odds Ratio
Proportional Hazards Models
Stroke / epidemiology

Substances

Hypoglycemic Agents